Palmar plantar erythrodysesthesia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]

Overview

Palmar plantar erythrodysesthesia (PPE) has been reported to occur in 6 – 64% of patients treated with different chemotherapy regimens. However, the exact incidence of PPE is unknown, as most reports are isolated case reports or short case series.

Epidemiology and Demographics

Incidence

Based on some case series, palmar plantar erythrodysesthesia (PPE) has been reported to occur in 6 – 64% of patients treated with different chemotherapy regimens. ^[1]

References

↑ L. Hueso, O. Sanmartin, E. Nagore, R. Botella-Estrada, C. Requena, B. Llombart, C. Serra-Guillen, A. Alfaro-Rubio & C. Guillen. “[Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases]”. Actas dermo-sifiliograficas. PMID 18394404.

[1] L. Hueso, O. Sanmartin, E. Nagore, R. Botella-Estrada, C. Requena, B. Llombart, C. Serra-Guillen, A. Alfaro-Rubio & C. Guillen. “[Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases]”. Actas dermo-sifiliograficas. PMID 18394404.

[1]